Reported Earnings • Aug 26
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: kr.1.18m (down 69% from 2Q 2024). Net loss: kr.2.77m (loss widened 337% from 2Q 2024). Reported Earnings • May 25
First quarter 2025 earnings released First quarter 2025 results: Revenue: kr.244.0k (down 65% from 1Q 2024). Net loss: kr.2.93m (loss widened 13% from 1Q 2024). Announcement • May 21
Dancann Pharma A/S Receives Regulatory Approval for Bedrolite and Bedrobinol from the Danish Medicines Agency Under the Danish Pilot Programme DanCann Pharma A/S announced that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite®? and Bedrobinol®? under the Danish Medicines Agency. The approval of these new products is in line with the Company's communicated guidance and is expected to have a positive impact on sales performance going forward. DanCann Pharma has received confirmation of regulatory approval for the distribution of two additional products in the Danish medicinal cannabis market from the Danish Medicines Agency. This regulatory milestone further strengthens DanCann Pharma's strategic positioning and leadership within Denmark's tightly regulated framework for medicinal cannabis and underscores the Company's ongoing commitment to broadening patient access to standardized, high-quality cannabinoid-based therapies. Bedrolite®? and bedrobinol®? Bedrolite®? represents the first Cannabidiol ("CBD")-dominant granulate product to be approved under the Pilot Programme in Denmark. The product contains approximately 9% CBD and less than 1% delta-9-tetrahydrocannabinol ("THC"). Inhalation as a delivery method allows for rapid onset of action, typically within 5-10 minutes, which is advantage for managing acute symptoms. The method also enables precise self-titration by patients and avoids first-pass hepatic metabolism, thereby improving bioavailability compared to oral formulations (e.g. oils, extracts and tinctures). Under the current framework of the Danish Pilot Programme for medicinal cannabis, the products are prescribable by all licensed medical practitioners and are eligible for public reimbursement in accordance with the reimbursement scheme established under the Pilot Programme for medicinal cannabis. Under the Danish pilot Programme for medicinal cannabis, patients are eligible for government reimbursement covering 50% of their annual treatment costs, up to a maximum of DKK 20,000 per year. The expected retail price for the newly approved products (Bedrolite®? and Bedrombinol®? in 5-gram units) is approximately DKK 500.00, inclusive of VAT and pharmacy fees. After reimbursement, the effective out-of-pocket cost to the patient is approximately DKK 250.00 per unit--equivalent to around DKK 50.00 per gram. This cost may be further reduced for patients who are members of the private health insurance scheme "Danmark", depending on their membership group and applicable coverage terms. 
